A bipartisan U.S. House committee is investigating clinical drug trials conducted by Merck and AbbVie in China, including studies linked to Chinese military facilities and sites in Xinjiang, according to multiple reports. The committee requests information from the companies about the scope and oversight of hundreds of clinical studies, focusing in particular on trial locations such as military hospitals. Lawmakers are seeking details on what due diligence the firms performed regarding the conduct and context of the trials, as well as the processes they use to protect data and ensure compliance with applicable standards. The inquiry centers on whether the companies’ trial practices adequately address risks associated with working in sensitive settings, including military-run medical facilities and detention-adjacent regions such as Xinjiang. The committee’s requests aim to clarify how the companies monitor study conduct, manage patient and data protections, and validate that trial sites meet expected requirements. The companies have been asked to provide documentation and other information to support the committee’s review.